Ethnic disparities relative to disease features and outcomes in children with acute myeloid leukemia
- 7 March 2017
- journal article
- research article
- Published by Wiley in Pediatric Blood & Cancer
- Vol. 64 (9)
Abstract
Hispanics with acute leukemias have poorer outcomes than non‐Hispanic whites (NHWs), despite an increased likelihood of favorable prognostic features. We reviewed medical records from 167 children ages 0–18 years diagnosed with de novo AML over an 18‐year period at Texas Children's Cancer Center, among whom 129 self‐identified as Hispanic or NHW. Although Hispanics were significantly more likely to have the favorable prognostic cytogenetic feature t(8;21) (P = 0.04), the expected survival benefit was not observed. This lack of survival benefit was primarily due to significantly poorer event‐free and overall survival among Hispanics treated with upfront stem cell transplantation after achieving first clinical remission (P = 0.008).Keywords
Funding Information
- St. Baldrick's Foundation
This publication has 21 references indexed in Scilit:
- Racial disparities in the survival of American children, adolescents, and young adults with acute lymphoblastic leukemia, acute myelogenous leukemia, and Hodgkin lymphomaCancer, 2016
- Prognostic factors of childhood and adolescent acute myeloid leukemia (AML) survival: Evidence from four decades of US population dataCancer Epidemiology, 2015
- Racial and Ethnic Disparities in Cancer Survival by Neighborhood Socioeconomic Status in Surveillance, Epidemiology, and End Results (SEER) RegistriesJNCI Monographs, 2014
- Gemtuzumab Ozogamicin in Children and Adolescents With De Novo Acute Myeloid Leukemia Improves Event-Free Survival by Reducing Relapse Risk: Results From the Randomized Phase III Children's Oncology Group Trial AAML0531Journal of Clinical Oncology, 2014
- Disparities in cancer outcomes: Lessons learned from children with cancerPediatric Blood & Cancer, 2011
- Minimal residual disease-directed therapy for childhood acute myeloid leukaemia: results of the AML02 multicentre trialThe Lancet Oncology, 2010
- Childhood and adolescent cancer survival in the US by race and ethnicity for the diagnostic period 1975‐1999Cancer, 2008
- Ethnicity and survival in childhood acute myeloid leukemia: a report from the Children's Oncology GroupBlood, 2006
- Randomized use of cyclosporin A (CsA) to modulate P-glycoprotein in children with AML in remission: Pediatric Oncology Group Study 9421Blood, 2006
- Autologous Bone Marrow Transplantation versus Intensive Consolidation Chemotherapy for Acute Myeloid Leukemia in ChildhoodNew England Journal of Medicine, 1996